4.6 Letter

Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Oncology

Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome- A Systematic Review

Unaiza Faizan et al.

Summary: POEMS syndrome is a rare paraneoplastic disorder associated with plasma cell neoplasia. Treatment options include chemotherapy, stem cell transplantation, and medication therapy. Combinations of treatments have shown good efficacy and safety profiles.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Article Hematology

POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management

Angela Dispenzieri

Summary: POEMS syndrome is a paraneoplastic syndrome caused by an underlying plasma cell neoplasm, with distinct clinical features and diagnostic criteria. Risk stratification is needed for therapeutic strategies in order to achieve optimal outcomes.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Letter Oncology

Treatment and outcomes of POEMS syndrome: changes in the past 20 years

Yan-ying Yu et al.

BLOOD CANCER JOURNAL (2021)

Review Oncology

Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome A Review

Jack Khouri et al.

Summary: POEMS syndrome is a rare plasma cell disorder characterized by demyelinating peripheral neuropathy and clonal plasma cell proliferation. Early diagnosis is essential, as the syndrome may be mistaken for other diseases due to its rarity. Treatment aims to alleviate symptoms and achieve complete hematologic and VEGF responses.

JAMA ONCOLOGY (2021)

Review Hematology

Current Updates on the Management of AL Amyloidosis

Marwa Elsayed et al.

Summary: AL amyloidosis is a rare and fatal disease caused by the aggregation of misfolded proteins in the extracellular matrix. Treatment strategies for this disease have historically been based on therapies used for multiple myeloma, but success rates vary. Ongoing research is focused on improving treatment outcomes for AL amyloidosis through updates to clinical guidelines and therapeutic approaches.

JOURNAL OF HEMATOLOGY (2021)

Article Hematology

Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy

Mohamed A. Kharfan-Dabaja et al.

Summary: Allogeneic hematopoietic cell transplantation (allo-HCT) has made significant advances in recent years, broadening its indications and improving outcomes. Despite achieving consensus on certain definitions, challenges remain, such as the lack of agreement on delayed engraftment.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Article Hematology

Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden

Robert F. Cornell et al.

Summary: The study analyzed the outcomes of AL amyloidosis patients undergoing autologous hematopoietic cell transplant with pre-transplant induction chemotherapy. Results showed that patients receiving induction had lower relapse/progression and better progression-free survival at 2 years, while overall survival was similar between the two groups.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Article Hematology

Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan

Chika Kawajiri-Manako et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)

Letter Medicine, General & Internal

Daratumumab for POEMS Syndrome

Maliha Khan et al.

MAYO CLINIC PROCEEDINGS (2018)

Article Hematology

Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience

Taxiarchis V. Kourelis et al.

AMERICAN JOURNAL OF HEMATOLOGY (2016)

Article Hematology

POEMS syndrome: definitions and long-term outcome

A Dispenzieri et al.